Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Journal of Clinical Oncology (JCO)
Published October 28, 2026
KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With P...
October 29, 2026
Medspoke
Medspoke
Journal of Clinical Oncology (JCO)
Published October 28, 2026
00:00
--:--
Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival,...
October 29, 2026
Share
Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study.
https://www.medspoke.co/channel_journal?id=686&tap_id=16631
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
The Lancet Oncology
Published October 28, 2026
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway mod...
October 29, 2026
Why are you reporting this TALK?
